Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700722 · ClinicalTrials.gov registry record
Synuclein-One Study
A clinical trial of Parkinson Disease and Multiple System Atrophy, sponsored by CND Life Sciences.
- Completed
- Registry status
- 428
- Enrollment target
- 20
- Study locations
NCT04700722 is a study of Parkinson Disease and Multiple System Atrophy that has completed, run by CND Life Sciences. The registered enrollment target is 428 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04700722, a study of Parkinson Disease and Multiple System Atrophy, has completed, sponsored by CND Life Sciences.
- COMPLETED
- Registry status
- 428 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Skin Biopsy
Study Locations (20)
Florida
- Aventura Neurology - Aventura
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- UF College of Medicine - Gainesville
- Parkinson's Disease Treatment Center SWFL - Port Charlotte
Arizona
- MD First Research - Chandler
- CND Life Sciences - Phoenix
- Movement Disorders Center of Arizona - Scottsdale
California
- The Neuro Center - Carlsbad
- Providence St. John's Health - Santa Monica
Massachusetts
- Boston Medical Center - Boston
- Beth Israel Lahey Health - Boston
New York
- NYU Medical Center - New York
- SouthShore Neurologic - Patchogue
Colorado
- Rocky Mountain Movement Disorders Center, PC - Englewood
Illinois
- NorthShore University Health System - Evanston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2023-11-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04700722
The ClinicalTrials.gov registry entry for NCT04700722 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 428 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower). The listed sponsor is CND Life Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Skin Biopsy is the first listed.
NCT04700722 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04700722 about?
NCT04700722 is a clinical study titled "Synuclein-One Study". The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodeg...
What is the current status of trial NCT04700722?
This trial is currently completed. The enrollment target is 428 participants. The study started on 2021-01-04. Estimated completion is 2023-11-08.
What conditions does trial NCT04700722 study?
This clinical trial studies the following conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure.
What interventions are being tested in trial NCT04700722?
The interventions under investigation include: Skin Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04700722?
This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04700722 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.